Scientific Staff

Date of Birth :15- 2-1982

Department : Translational Virology

Educational Qualification : PhD

Research experience :

“Mechanism of Natural Killer Cell Activation in controlling Dengue virus infection in Humanized mouse model”

In humanized mouse model of Dengue infection, human NK cell control viremia in Interferon-? dependent manner. NK cell activation is dependent on cell to cell contact with virus infected dendritic cells.

Postdoctoral Fellow, Department of Pathology, Saint Louis University, Saint Louis, USA “Hepatitis C Virus mediated innate immunity”

Area of interest : Mother and Child Health, Epigenetics, Placental Nutrient Transport

Postdoctoral Fellow, Department of Pathology, Saint Louis University, Saint Louis, USA “Hepatitis C Virus mediated innate immunity”

• Hepatitis C virus induced autophagy and its role in viral pathogenesis
  HCV infection impairs innate immune response by inducing autophagy in hepatocytes. Autophagy induction also help virus to facilitate infectious virus particle production and establish infection in hepatocytes
• Molecular mechanism involved in evasion of innate immune response by Hepatitis C virus
  HCV infection suppresses interferon alpha induced interferon stimulated gene expression proteins, such as, ISG56 and IFITM1 in hepatocytes. HCV directly reduces interferon alpha production by inhibiting nuclear translocation of IRF7.
• HCV infection and modulation of microRNA in virus mediated pathogenesis
  MicroRNA profiling in HCV infected patients reveals gradual increase in miR-20a expression with increase in severity of liver fibrosis. HCV infection suppresses expression of miR-181c to enhance HOXA1 expression and cell growth in hepatocytes.

Ph.D, Hepatitis Department, National Institute of Virology, Pune, Maharashtra, India “Development of Combined DNA Vaccine for Hepatitis B and E Viruses”

• Characterization of humoral and cellular response in candidate combination vaccine utilizing liposome encapsulation approaches of DNA, protein and DNA + protein formulations against hepatitis B and hepatitis E in mice
  • Anti-HBs and anti-HEV IgG titres of individual component of DNA+ protein formulations were comparable to respective titres in combination vaccine of DNA+ protein formulations
  • Equivalent levels of IgG1 and IgG2a were observed in combination vaccine group against both components of the vaccine.
  • Combination vaccine group showed mixed Th1/Th2 cytokine profile.

Honors and Awards:

memberships

• American Society of Virology, 2012

Publications

• Shrivastava S, Tiraki D, Diwan A, Lalwani SK, Modak M, Mishra AC, Arankalle VA. Co-circulation of all the four dengue virus serotypes and detection of a novel clade of DENV-4 (genotype I) virus in Pune, India during 2016 season. PLoS One. 2018 Feb 22.
• Mishra AC, Arankalle VA, Gadhave SA, Mahadik PH, Shrivastava S, Bhutkar M, Vaidya VM. Stratified sero-prevalence revealed overall high disease burden of dengue but suboptimal immunity in younger age groups in Pune, India. PLoS Negl Trop Dis. 2018 Aug 6.
• Kulkarni R, Shrivastava S, Patil HP, Tiraki D, Mishra AC, Arankalle VA. Correlation of serostatus and viraemia levels among Indian dengue patients at the time of first diagnosis. Trans R Soc Trop Med Hyg. 2020 Jul.
• Kulkarni-Munje A, Palkar S, Shrivastava S, Lalwani S, Mishra AC, Arankalle VA. Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity. Immun Inflamm Dis. 2021 Jun.
• Patil HP, Rane PS, Shrivastava S, Palkar S, Lalwani S, Mishra AC, Arankalle VA. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. Viral Immunol. 2021 Apr.
• Shrivastava S, Patil HP, Mhaske ST, Palkar S, Lalwani S, Mishra AC, Arankalle VA. Isolation and genetic characterization of SARS-CoV-2 from Indian patients in a single family without H/O travel abroad. Virus Genes. 2021 Jun.
• Shrivastava S, Palkar S, Shah J, Rane P, Lalwani S, Mishra AC, Arankalle VA. Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India. Am J Trop Med Hyg. 2021 Jun 17.
• Kulkarni R, Shrivastava S, Patil HP, Kore P, Rane P, Palkar S, Lalwani S, Mishra AC, Arankalle VA. Performance assessment of SARS-CoV-2 IgM & IgG ELISAs in comparison with plaque reduction neutralization test. Indian J Med Res. 2021 May.
• Shrivastava S, Chelluboina S, Jedge P, Doke P, Palkar S, Mishra AC, Arankalle VA. Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients. Front Cell Infect Microbiol. 2021 Oct.
• Shrivastava S, Mhaske ST, Modak MS, Virkar RG, Pisal SS, Mishra AC, Arankalle VA. Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India. Arch Virol. 2022 Feb.
• Doke P, Gothankar JS, Doke PP, Kulkarni MM, Khalate KK, Shrivastava S, Patil JR, Arankalle VA. Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection. Microbes Infect. 2022 Jun.
• Vedpathak S, Sharma A, Palkar S, Bhatt VR, Patil VC, Kakrani AL, Mishra A, Bhosle D, Arankalle VA, Shrivastava S. Platelet derived exosomes disrupt endothelial cell monolayer integrity and enhance vascular inflammation in dengue patients. Front Immunol. 2024 Jan 3.
• Vedpathak S, Palkar S, Mishra A, Arankalle VA, Shrivastava S. Dengue infection changes the expressions of CD154 and CD148 in human platelets. Virus Res. 2025 Jan.
• Chelluboina S, Mishra AC, Arankalle VA, Shrivastava S. Age-specific kinetics of neutralizing antibodies and infection enhancement among ≤1 year-old Indian infants. Front Cell Infect Microbiol. 2025 Feb 27.
• Arankalle VA, Shrivastava S, Cherian S, Gunjikar RS, Walimbe AM, Jadhav SM, Sudeep AB, Mishra AC. Genetic divergence of Chikungunya viruses in India (1963- 2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol 2007; 88:1967-76. Impact factor: 3.36
• Arankalle VA, Lole KS, Deshmukh TM, Srivastava S, Shaligram US. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime- protein-boost and DNA-protein encapsulated in liposomes. Vaccine 2009; 27:1032-9. (Ph.D work) Impact factor: 3.77
• Shrivastava S, Lole KS, Tripathy AS, Shaligram US, Arankalle VA. Development of candidate combination vaccine for hepatitis E and hepatitis B: a liposome encapsulation approach. Vaccine 2009; 27:6582-8. (Ph.D work) Impact factor: 3.77
• Raychoudhuri A, Shrivastava S, Steele R, Dash S, Kanda T, Ray R, Ray RB. Hepatitis C virus infection impairs IRF-7 translocation and interferon-alpha synthesis in immortalized human hepatocytes. J Virol 2010; 84:10991-8. Impact factor: 5.08
• Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB. Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology 2011; 53:406-414. Impact factor: 12.00
• Raychoudhuri A, Shrivastava S#, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85:12881-9. (#shared first author) Impact factor: 5.08
• Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 2012; 86:6315-22. Impact factor: 5.08
• Shrivastava S, Bhanja Chowdhury J, Steele R, Ray R, Ray RB. Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates mTOR Signaling. J Virol 2012; 86:8705-12. Impact factor: 5.08
• Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. Hepatitis C Virus infection modulates interferon stimulatory gene IFITM1 by up- regulating miR-130a. J Virol 2012; 86:10221-5. Impact factor: 5.08
• Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB. Upregulation of circulating miR-20a is correlated with Hepatitis C Virus mediated liver disease progression. Hepatology. 2013; 58:863-71 (selected as editorial of Hepatology journal in September 2013) Impact factor: 12.00
• Bittar C, Shrivastava S, Bhanja Chowdhury J, Rahal P, Ray R. Hepatitis C Virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm. PLoS One 2013; 8:e62581. Impact factor: 4.09
• . Shrivastava S, Mukherjee A, Ray R, Ray RB. Hepatitis C Virus Induces Interleukin-1ß (IL-1ß)/IL-18 in Circulatory and Resident Liver Macrophages. J Virol 2013; 87:12284-90. Impact factor: 5.08
• Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013; 5:479-486. Review
• Shrivastava S, Ray RB. Hepatitis C virus infection, autophagy and innate immune response. In: Hayat MA, ed. Autophagy. Cancer, Other Pathologies, Inflammation, Immunity, Infection and Aging. Academic Press, Elsevier. 2014; 3:164-190.
• . Mukherjee A, Shrivastava S#, Bhanja Chowdhury J, Ray R, Ray RB. Transcriptional Suppression of miR-181c by Hepatitis C Virus Enhances Homeobox A1 Expression. J Virol 2014; 88:7929-40. (# shared first author) (selected as “Spotlight” in July issue of Journal of Virology) Impact factor: 5.08
• Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: Role in Hepatitis C Virus pathogenesis. Genes Dis. 2015; 2:35-45. Review
• Shrivastava S, Devhare P, Sujijantarat N, Steele R, Kwon YC, Ray R, Ray RB. Knockdown of autophagy inhibits infectious hepatitis C virus release by exosomal pathway. J Virol 2015 Nov 18. pii: JVI.02383-15. (Ahead of print)

WORKSHOPS and CONFERENCES:

References

• Graduate Advisor: Dr. V A Arankalle, Scientist “G” & Head, Hepatitis Division, Microbial Containment Complex, National Institute of Virology, 130/1 Sus Road, Pashan, Pune - 411021, Maharashtra, India. Email: [email protected]
• Postdoctoral Advisor: Dr. Ratna B. Ray, Professor, Department of Pathology, Edward A Doisy Research Center, RM 207, Saint Louis University, 1100 South Grand Blvd., Saint Louis, MO, 63104, USA. Email: [email protected]
• Dr. Ranjit Ray, Professor, Department of Internal Medicine, Edward A Doisy Research Center, RM 823, Saint Louis University, 1100 South Grand Blvd., Saint Louis, MO, 63104, USA. Email: [email protected]